Aldeyra Therapeutics (ALDX) Depreciation and Depletion (2014 - 2026)
Aldeyra Therapeutics (ALDX) posted Depreciation and Depletion of $66599.0 for Q1 2026, up 2.28% on a QoQ basis from $65116.0 in Q4 2025, and up 9.34% year-over-year from $60912.0 in Q1 2025.
Aldeyra Therapeutics (ALDX) Depreciation and Depletion (2014 - 2026) Analysis & Trends
Aldeyra Therapeutics' Depreciation and Depletion history runs 12 years deep, the most recent figure standing at $66599.0 for Q1 2026.
- Quarterly Depreciation and Depletion rose 9.34% year-over-year to $66599.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $257680.0 (up 3.11% YoY) and the FY2025 annual result came in at $251993.0, up 0.95% from the prior year.
- Depreciation and Depletion was $66599.0 for Q1 2026 at Aldeyra Therapeutics, up from $65116.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $66972.0 in Q1 2023 and bottomed at $60632.0 in Q1 2024.
- A 5-year average of $64100.1 and a median of $64340.0 in 2023 frame the typical range for Depreciation and Depletion.
- Annual changes were most pronounced in 2024 — Depreciation and Depletion dropped 9.47% — and 2026, when it advanced 9.34%.
- Aldeyra Therapeutics' Depreciation and Depletion stood at $66643.0 in 2022, then decreased by 0.26% to $66469.0 in 2023, then fell by 3.15% to $64373.0 in 2024, then grew by 1.15% to $65116.0 in 2025, then increased by 2.28% to $66599.0 in 2026.
- Business Quant data shows ALDX's Depreciation and Depletion at $66599.0 in Q1 2026, $65116.0 in Q4 2025, and $63683.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 39.39 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | 66,599.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66,599.00 |
| Mar 31, 2026 | 66,599.00 |
| Dec 31, 2025 | 65,116.00 |
| Dec 31, 2025 | 65,116.00 |
| Sep 30, 2025 | 63,683.00 |
| Sep 30, 2025 | 63,683.00 |
| Jun 30, 2025 | 62,282.00 |
| Jun 30, 2025 | 62,282.00 |
| Mar 31, 2025 | 60,912.00 |
| Mar 31, 2025 | 60,912.00 |
| Dec 31, 2024 | 64,373.00 |
| Dec 31, 2024 | 64,373.00 |
| Sep 30, 2024 | 62,987.00 |
| Sep 30, 2024 | 62,987.00 |
| Jun 30, 2024 | 61,631.00 |
| Jun 30, 2024 | 61,631.00 |
| Mar 31, 2024 | 60,632.00 |
| Mar 31, 2024 | 60,632.00 |
| Dec 31, 2023 | 66,469.00 |
| Dec 31, 2023 | 66,469.00 |